By Suherman Candra Maholtra 
In a significant advancement for preventative dermatology, a large-scale retrospective study involving more than 33,000 patients has confirmed that nicotinamide, a specific form of vitamin B3, significantly reduces the risk of developing new non-melanoma skin cancers. The research, which utilized the extensive medical databases of the U.S. Department of Veterans Affairs (VA), provides the most robust evidence to date supporting a practice that has been widely recommended but difficult to verify on a population-wide scale. By analyzing the outcomes of veterans who were prescribed the supplement, researchers have identified a critical "window of opportunity" for intervention, suggesting that the timing of treatment may be just as important as the treatment itself.
The Evolution of Nicotinamide in Preventative Care
The clinical interest in nicotinamide as a chemopreventative agent began in earnest nearly a decade ago. In 2015, a landmark Phase 3 clinical trial known as the ONTRAC (Oral Nicotinamide to Prevent Actinic Keratoses) study was published in the New England Journal of Medicine. That study followed 386 participants and found that taking 500 milligrams of nicotinamide twice daily reduced the incidence of new non-melanoma skin cancers by 23% compared to a placebo group. Following these results, dermatologists globally began recommending the over-the-counter supplement to high-risk patients, particularly those with a history of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC).
However, while the ONTRAC study was influential, its small sample size and controlled environment left questions regarding its efficacy in the general population. Because nicotinamide is an inexpensive, over-the-counter supplement, tracking its usage through standard medical records is notoriously difficult; most patients purchase it at pharmacies or health food stores without a formal prescription that enters their electronic health record. This "data gap" has persisted for years, preventing researchers from conducting the large-scale longitudinal studies necessary to confirm the 2015 findings in a real-world setting.
To bridge this gap, a research team led by Lee Wheless, MD, PhD, an assistant professor of Dermatology and Medicine at Vanderbilt University Medical Center, turned to the Veterans Affairs (VA) Corporate Data Warehouse. Unlike most private health systems, the VA maintains a comprehensive formulary where nicotinamide is listed and tracked when provided to veterans. This unique data set allowed researchers to observe the long-term outcomes of thousands of patients in a way that was previously impossible.
A Deep Dive into the Data: 33,833 Veterans
The study cohort was massive, comprising 33,833 veterans who met the criteria for inclusion. The researchers focused on individuals who had received a baseline treatment of 500 milligrams of nicotinamide twice daily for a period exceeding 30 days. Within this group, 12,287 patients were identified as nicotinamide users, while a control group of 21,479 patients had not used the supplement.
The findings revealed a 14% overall decrease in the risk of developing new skin cancers among those taking the supplement. While this figure is slightly lower than the 23% reported in the 2015 ONTRAC study, the scale of the VA study provides a more statistically significant look at the supplement’s impact across a diverse, aging population.
The most striking discovery, however, emerged when the data was segmented by the timing of the supplement’s initiation. For patients who began taking nicotinamide immediately after their first skin cancer diagnosis, the risk reduction was a staggering 54%. This suggests that the supplement is most effective when used as an early intervention. Conversely, the benefit appeared to diminish for patients who did not start the regimen until they had already developed multiple skin cancers.
The Biological Mechanism: Why Vitamin B3?
To understand why nicotinamide is effective, it is necessary to look at the cellular impact of ultraviolet (UV) radiation. When skin is exposed to UV light, it causes DNA damage and depletes cellular energy in the form of adenosine triphosphate (ATP). This energy depletion is a double-edged sword: it both causes the damage and robs the cells of the energy required to fuel the enzymes responsible for DNA repair.
Nicotinamide acts as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for ATP production. By supplementing with nicotinamide, patients are essentially "refueling" their skin cells, providing the necessary energy to enhance DNA repair mechanisms and reduce the inflammatory response triggered by UV exposure. Unlike niacin (another form of vitamin B3), nicotinamide does not cause "flushing" or low blood pressure, making it a well-tolerated option for long-term use.
The study noted that the protective effect was particularly strong for cutaneous squamous cell carcinoma (SCC). SCC is the second most common form of skin cancer and has a higher potential for metastasis compared to basal cell carcinoma. The ability of a simple vitamin supplement to significantly lower the risk of SCC represents a major public health opportunity, especially for the veteran population which often sees high rates of sun-related skin damage due to outdoor service.
Implications for Clinical Practice and Guidelines
Current dermatological guidelines are somewhat vague regarding the precise moment a patient should begin a nicotinamide regimen. Many practitioners wait until a patient shows signs of "field cancerization"—a state where a large area of skin has been so damaged by the sun that it repeatedly produces new precancerous lesions and tumors.
Dr. Lee Wheless noted that the study’s findings should prompt a shift in how clinicians approach prevention. "These results would really shift our practice from starting it once patients have developed numerous skin cancers to starting it earlier," Wheless stated. He emphasized that the goal should be to identify patients at the onset of their skin cancer history to maximize the supplement’s protective potential.
However, Wheless also cautioned that nicotinamide is not a "one-size-fits-all" solution. The data indicated that roughly half of the patients who develop one skin cancer will never develop another, meaning that universal supplementation might not be necessary. The challenge for the medical community moving forward will be to better identify the specific "high-risk" sub-group that is most likely to benefit from early intervention.
Findings in Immunocompromised Populations
The research team also examined a specific sub-group of 1,334 patients who were immunocompromised, largely due to solid organ transplants. Transplant recipients are at a significantly higher risk for skin cancer—sometimes up to 100 times higher than the general population—because the immunosuppressant drugs required to prevent organ rejection also hinder the body’s ability to detect and destroy early-stage cancer cells.
In this high-risk group, the results were more nuanced. While there was a trend toward fewer cases of squamous cell carcinoma among early users of nicotinamide, the overall risk reduction for the immunocompromised group did not reach statistical significance. This suggests that while nicotinamide helps with DNA repair, it may not be powerful enough to overcome the significant immune deficits present in transplant patients. For these individuals, more aggressive preventative measures, such as frequent dermatological screenings and strict photoprotection, remains the standard of care.
Economic and Public Health Impact
The implications of this study extend beyond clinical outcomes into the realm of healthcare economics. Non-melanoma skin cancer is the most common malignancy in the United States, with millions of new cases diagnosed annually. The cost of treating these cancers—involving surgical excisions, Mohs surgery, and follow-up care—runs into the billions of dollars each year.
Nicotinamide, by contrast, is highly cost-effective. A monthly supply typically costs less than $10 to $15. If a 14% to 54% reduction in new cases can be achieved through a low-cost, low-risk oral supplement, the potential savings to the healthcare system, and specifically to the VA system, are immense. Furthermore, reducing the surgical burden on elderly patients improves their quality of life by avoiding the scarring, potential infections, and anxiety associated with repeated procedures.
Research Collaboration and Funding
This comprehensive study was made possible through a collaboration of experts from the Vanderbilt University Medical Center and the VA Tennessee Valley Healthcare System. The work was supported by a Department of Veterans Affairs grant (IK2CX002452), highlighting the importance of federal funding in conducting large-scale "Big Data" medical research.
The co-authors of the study included Katyln Knox, Rachel Weiss, Siwei Zhang, PhD, Lydia Yao, MS, Yaomin Xu, PhD, and Kyle Maas. Their collective effort in cleaning and analyzing the VA’s massive data warehouse has provided a clearer roadmap for skin cancer prevention.
Future Outlook: Refining Prevention Strategies
As the medical community digests these findings, the next step will likely involve the integration of these results into formal clinical guidelines. The study reinforces the importance of "preventative maintenance" in dermatology, moving the field closer to a model of proactive care rather than reactive treatment.
Future research will likely focus on whether combining nicotinamide with other preventative measures—such as topical retinoids or specific dietary changes—could further drive down cancer rates. For now, the message for patients with a fresh diagnosis of skin cancer is clear: a conversation with their dermatologist about starting vitamin B3 sooner rather than later could significantly alter their long-term health trajectory.
The VA study stands as a testament to the power of large-scale data in validating clinical intuitions. It confirms that for many, a simple, inexpensive vitamin is a potent tool in the fight against the world’s most common cancer, provided it is used at the right time. For veterans and the general public alike, this research offers a practical, science-backed strategy to protect the skin and reduce the burden of future disease.
